A 2-year follow-up of the randomized, placebo-controlled BANDIT trial shows that stopping baricitinib leads to a loss of therapeutic benefit, supporting its evaluation in earlier stages of type 1 ...

Experts at Old Dominion University highlighted economic challenges but forecast growth in Hampton Roads in 2025 during ODU's ...

Learn how ancient teeth have revealed new insights about the earliest farming communities, including how they treated ...

With an oversaturated market and tons of variety, buying a hybrid vehicle can get complicated. To demystify the process, ...